Drugs that have dual inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) produce better clinical efficacy against Alzheimer's disease (AD) than those that selectively inhibit one enzyme. A dual cholinesterase inhibitory-guided fractionation of Phyllanthus niruri leaves afforded isocorilagin, a bioactive tannin possessing good inhibitory activities against AChE (IC 50 : 0.49 μM) and BChE (IC 50 : 4.20 μM). Interestingly, isocorilagin was relatively 2-to 3-fold more potent than galanthamine, the clinically used inhibitor. The kinetic analyses suggested that isocorilagin was a non-competitive inhibitor for AChE and an uncompetitive inhibitor for BChE, with calculated Ki values of 1.49 μM and 2.86 μM, respectively. In silico molecular docking revealed that isocorilagin effectively blocked the substrate entry by forming hydrogen bonding with residues at the entrance of the AChE active site. With BChE, the compound completely docked inside and occupied the active site of the enzyme. This study demonstrated for the first time the potent cholinesterase inhibitory activities of isocorilagin, a promising lead that is worthy of further investigation.
Alzheimer's disease (AD) is the leading cause of dementia amongst elderly people. The etiology of AD is due to several closely related factors. The accumulation of -amyloid peptide into the senile plaques and the formation of neurofibrillary tangles comprising the aggregates of hyper-phosphorylated tau proteins result in neuronal cell death that subsequently leads to the impairment of cholinergic neurotransmission [1] . Acetylcholine synthesis is remarkably reduced in AD patients, leading to cognitive decline. Hitherto, the most widely used drugs for the management of AD include cholinesterase inhibitors, which primarily inhibit acetylcholinesterase (AChE), thereby sustaining the level of acetylcholine and improve cognition. Acetylcholine is also broken down by another cholinesterase, butyrylcholinesterase (BChE). The importance of this enzyme was demonstrated by several studies, whereby acetylcholine regulation was increasingly dependent on BChE along with the decline of AChE as the disease progressed [2, 3] . Realizing the potential involvement of BChE in AD, any agent that has dual inhibition of both enzymes, could, therefore, provide beneficial clinical efficacy. Natural products, particularly medicinal plants, have contributed significantly towards drug discovery and development against AD. Our random screening of some Malaysian medicinal plants has highlighted Phyllanthus niruri as one of the potential dual inhibitors of AChE and BChE. P. niruri, locally known as "dukong anak", is a common weed that is widely distributed in tropical and sub-tropical countries. The plant has been extensively studied for its phytochemicals and pharmacological properties [4] [5] [6] . Previously, we reported the antihyperuricemic effect of P. niruri lignans [4, 5] .
P. niruri methanol extract showed potential inhibitory activity against both AChE and BChE. The IC 50 values and enzyme selectivity indices of the methanol extract, fractions, sub-fractions, and bioactive compound are summarized in Table 1 . Upon fractionation of the methanolic extract of P. niruri, the inhibitory activity was found concentrated in fraction R3. Further subfractionation of this afforded 8 sub-fractions, with S4 being the most active, possessing lower IC 50 values than fraction R3 against both AChE and BChE. Purification of sub-fraction R4 yielded L2 with more potent inhibitory activity, with IC 50 values of 0.56 μg/mL for AChE and 4.61 μg/mL for BChE. Upon further purification of L2, a cholinesterase inhibitor, isocorilagin ( Figure 1 ) was successfully isolated, with IC 50 values of 0.31 μg/mL (0.49 μM) for AChE and 2.66 μg/mL (4.20 μM) for BChE, being 2-and 3-fold more potent than galanthamine on AChE and BChE inhibition, respectively. Despite inhibiting both enzymes, isocorilagin displayed selectivity towards AChE than BChE, similar to that of galanthamine. The Lineweaver-Burk plot was used to study the types of inhibition and enzyme kinetics of isocorilagin. It was found to be a noncompetitive inhibitor of AChE and an uncompetitive inhibitor of BChE ( Figure 2 isocorilagin on AChE showed no change of K m , but decreased V max , indicating a non-competitive inhibition. On BChE, increasing concentrations of isocorilagin decreased both K m and V max , indicating an uncompetitive inhibition ( Table 2 ).
Molecular docking of isocorilagin was performed to investigate the binding interactions and orientations of the inhibitor. Isocorilagin inhibited AChE by binding at loci different from the active site. Analysis revealed that isocorilagin forms strong hydrogen bonds with the side chain residues at the entrance of the active site gorge, such as Asp285, Ser286 and Arg289, as well as strong π-π stacking interaction with Trp279 at the peripheral anionic site of the enzyme (Figure 3) . The compound did not wholly enter the active site, but efficiently blocked the entry of acetylcholine into it. With BChE, isocorilagin was completely docked inside the active site of the enzyme and displayed a good docking score with free energy binding of -13.5 kcal/mol. It showed strong π-π stacking with the Trp82 residue at the -anionic site along with hydrogen bonding to the Leu286 residue at the peripheral anionic site and Gly116 at the oxyanion hole. These binding interactions provided effective accommodation of isocorilagin inside the active site cavity, thus blocking the substrate from occupying the active site (Figure 3 ). The peripheral anionic site is the main target of many pharmacologically important compounds (donepezil and huperzine A) rather than toxins such as nerve agents and organophosphates. The deposition of amyloid plaque in AD may be mediated by interaction of -amyloid with the peripheral anionic site of AChE [7] . Based on the interactions at the peripheral anionic and -anionic sites, isocorilagin showed similar mechanisms to those of galanthamine and donepezil. Isocorilagin may be further developed to combine with these drugs as an adjuvant for potential symptomatic treatment of AD to halt the progression of the disease.
In conclusion, isocorilagin, a potent inhibitor of cholinesterase enzymes, was isolated from Phyllanthus niruri. It displayed inhibition of both AChE and BChE, and had low micromolar IC 50 values. Interestingly, it was found to be 2-to 3-fold more potent than the clinically used inhibitor, galanthamine. Enzymatic kinetics analyses revealed that the inhibition modes of isocorilagin were non-competitive against AChE and uncompetitive against BChE. In silico molecular docking revealed that isocorilagin inhibited AChE by binding at the entrance of the active site gorge, whereas it was completely docked in the active site of BChE. Isocorilagin may be a potential lead for the discovery of new cholinesterase inhibitors.
Experimental
General procedure: Column chromatography was performed on a resin of styrene and divinylbenzene (Diaion HP20, Mitsubishi; Tokyo, Japan), silica gel (Merck No. 9385; Darmstadt, Germany) and Sephadex TM LH-20 (Amersham Bioscience; Uppsala, Sweden). The UV spectrum was measured on a Perkin Elmer Lambda 45 UV/VIS spectrometer (Perkin Elmer Instruments; CT, USA), and the IR spectrum on a Nexus FTIR (Thermo Nicolet Corp.; WI, USA). The MS was measured on a microTOF-QII (Bruker Biospin AG; Thailand) spectrometer. NMR spectra were obtained on a Bruker Avance III 500 spectrometer (Bruker Biospin AG; Thailand). Cholinesterase enzymes inhibitory-guided isolation: Powdered leaves (3 kg) were extracted with 15 L of methanol for a week. The extraction was repeated twice using the same amount of fresh solvent. The extracts were combined and evaporated under reduced pressure to yield 646.4 g of methanol extract. About 200 g of this was reconstituted in a minimal volume of methanol and passed through a 4.5 L resin column, eluted with solvent mixtures with stepwise increases of methanol in water (0, 30, 50, 80 and 100%, each 10 L) to yield 5 fractions, R1 to R5. R3 (10 g), in minimal methanol, was subjected to CC on a 500 mL silica gel column, and eluted sequentially with 1 L each of chloroform-methanol mixtures (10:0, 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8, 1:9 and 0:10). Fractions of 50 mL were collected and those displaying similar R f values on TLC were pooled into 8 sub-fractions, S1 to S8. S4 (500 mg) was further fractionated on a column of 150 mL Sephadex LH-20 and eluted with methanol into L1, L2 and L3. Isocorilagin (1) was isolated (L2) as a yellow amorphous powder. It was unambiguously assigned upon analyses of the UV, IR, NMR and MS data obtained and by comparison of these with those reported previously [8] .
Enzymatic assay: The cholinesterase inhibitory activity was performed following Ellman's microplate assay described by Ahmed and Gilani [9] . Briefly, for AChE inhibitory assay, 140 μL of 0.1 M sodium phosphate buffer (pH 8) was first added to each well of a 96-well microplate followed by 20 μL of the test sample (in 10 % methanol) and 20 μL of 0.09 unit/mL AChE. After 15 min of pre-incubation at 25°C, 10 μL of 10 mM 5,5′-dithiobis(2-nitrobenzoic acid) was added into each well followed by 10 μL of 14 mM acetylthiocholine iodide. The absorbance of the colored end-product was measured at 412 nm at various intervals for 30 min after initiation of the enzymatic reaction, by a BioTek PowerWave X340 Microplate Spectrophotometer (BioTek; Winooski, VT, United States). For BChE inhibitory assay, the same procedure was followed, except that the enzyme and substrate used were BChE from equine serum and S-butyrylthiocholine chloride, respectively. Galanthamine was used as reference standard. Each test sample was conducted in triplicate. A set of 5 concentrations was used to estimate the 50% inhibitory concentration (IC 50 ) for the bioactive plant extracts.
Types of inhibition and enzymatic kinetics:
The types of enzyme inhibition were determined following the in vitro assay procedure described above. The kinetics of enzyme inhibition were carried out in the absence and presence of isocorilagin (0, 0.39, 0.79 μM for AChE and 0, 3.15, 6.15 μM for BChE) with varying concentrations of substrates (3.5, 7.0, 14.0, 28.0 mM). The types of inhibition were determined by the Lineweaver−Burk plots, where the kinetic parameters K i , K m and V max were calculated.
Molecular modeling of isocorilagin:
Using Glide, (version 5.7, Schrödinger, LLC, New York, NY), isocorilagin was docked onto the active site of TcAChE derived from the three-dimensional structure of the enzyme complex with the anti-Alzheimer's drug, donepezil (PDB ID: 1EVE), and to human BChE derived from the complex of the enzyme with butyrylcholine substrate (PDB ID: 1P0P). The Receptor Grid Generation program was used to prepare the AChE and BChE grid and all the ligands were optimized by the LigPrep program using OPLS-2005 force field to generate the lowest energy state of ligands.
